JNJ Stock Overvalued by 38.1% Amid Insider Selling Activity
Johnson & Johnson (JNJ) stock closed at $267.57 on September 29, 2026, down 1.6% from the previous day. The company's share price has experienced significant volatility over the past year, with a 52-week range of $181.07 to $281.07.
According to GuruFocus' GF Value™ estimate, Johnson & Johnson is currently overvalued by 38.1%, with a fair value of $193.81 compared to its current market price of $267.57. The stock's high P/E ratio of 31.0x is also above its 5-year median of 24.4x.
The company's strong fundamentals are reflected in its GF Score™, which evaluates a company's financial health and growth potential. Johnson & Johnson has a score of 81/100, with strengths in profitability (9/10) and growth (8/10), but weaknesses in valuation (3/10) and momentum (3/10).
Insider activity suggests that those closest to the company are cautious about its future performance. Over the past 12 months, insiders have sold a net $154.6 million worth of stock, indicating a lack of confidence.